Drug Profile
LY 3857210
Alternative Names: LY-3857210Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Analgesics
- Mechanism of Action Purinoceptor P2X antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Back pain; Diabetic neuropathies; Neuropathic pain; Pain
Most Recent Events
- 01 Aug 2023 Eli Lilly and Company completes a phase II trial in Diabetic neuropathies, Neuropathic Pain and Pain in USA and Puerto Rico (PO) (NCT05620576)
- 18 Jul 2023 700358795 CTP push: Trial completion info added
- 18 Jul 2023 Eli Lilly and Company completes a phase II trial in Back pain in the US and Puerto Rico (PO) (NCT05630196)